About this trial
Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.
Eligibility criteria
Qualifiers
BMI 18.5-34.9 (inclusive) with a goal of being < 30 on average
Subject agrees to maintain their existing dietary patterns throughout the study period.
Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day.
Subject is willing and able to comply with the study protocol.
Disqualifiers
Individuals with a personal history of a psychiatric disorder.
Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.
Current or recent (< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.).
Alcohol consumption (>2 standard alcoholic drinks/day or >10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use).
Trial design
Treatments tested in this trial
- SageXtra
- Placebo
Treatment groups
Sponsors and collaborators
ESM Technologies, LLC
Lead sponsor
Exercise & Sport Nutrition Lab, Texas A&M University
Collaborator